Penumbra, Inc. filed its quarterly report on Form 10-Q with the SEC on October 29, 2026, covering the three and nine months ended September 30, 2026, reporting revenue of $410.1 million for the quarter and net income of $42.3 million.

Key Highlights

  • Quarterly revenue: $410,145 thousand for the three months ended September 30, 2026, compared to $354,685 thousand in the same period of 2025, according to the filing.
  • Nine-month revenue: $1,174,949 thousand for the nine months ended September 30, 2026, up from $1,018,280 thousand in the prior-year period.
  • Net income: $42,279 thousand for Q3 2026, compared to $45,851 thousand in Q3 2025; nine-month net income was $109,674 thousand versus $130,344 thousand in the prior year.
  • Diluted EPS: $1.07 per share for the three months ended September 30, 2026, compared to $1.17 in the prior-year quarter.
  • Total assets: $2,025,103 thousand as of September 30, 2026, up from $1,826,519 thousand at December 31, 2025.
  • Shares outstanding: 39,414,385 shares of common stock as of October 14, 2026, as disclosed in the filing.
  • Total stockholders' equity: $1,583,509 thousand at September 30, 2026, compared to $1,427,603 thousand at December 31, 2025.

Penumbra's Q3 2026 Financial Results: Revenue Growth and Margin Trends

Penumbra, Inc. (NYSE:PEN), a medical device company headquartered in Alameda, California, reported quarterly revenue of $410,145 thousand for the three months ended September 30, 2026, according to the filing. This compares to $354,685 thousand for the same quarter in 2025. Gross profit for Q3 2026 was $280,303 thousand, up from $240,416 thousand in Q3 2025. The company reported income from operations of $50,739 thousand for the quarter, compared to $48,838 thousand in the prior-year period.

For the nine months ended September 30, 2026, the filing shows total revenue of $1,174,949 thousand, against $1,018,280 thousand in the same period of 2025. Nine-month gross profit reached $798,658 thousand. Operating expenses for the nine-month period were $668,646 thousand, including $73,139 thousand in research and development and $595,507 thousand in sales, general and administrative costs. The provision for income taxes for the nine months ended September 30, 2026 was $34,517 thousand, compared to $11,149 thousand in the same prior-year period, a difference the filing reflects in the net income figures.

On the balance sheet, the company reported cash and cash equivalents of $254,282 thousand and marketable investments of $419,330 thousand as of September 30, 2026, compared to $186,897 thousand and $357,919 thousand, respectively, at December 31, 2025. Inventories stood at $459,132 thousand at quarter end, up from $431,549 thousand at year-end 2025. Total liabilities were $441,594 thousand at September 30, 2026, versus $398,916 thousand at December 31, 2025. Retained earnings grew to $347,365 thousand from $237,691 thousand at December 31, 2025, reflecting the net income generated over the nine-month period.

What Was Disclosed

Penumbra, Inc. disclosed its condensed consolidated financial statements for the quarter and nine months ended September 30, 2026, covering revenue, earnings, balance sheet positions, stockholders' equity activity, and comprehensive income, all presented on an unaudited basis as part of its Form 10-Q filing.